SKSoo Heon Kwak

Soo Heon Kwak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soo Heon Kwak has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Kyong Soo Park

    Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea

    29 shared publications
  • Kyong Soo Park

    Division of Endocrinology and Metabolism, Department of Internal Medicine Konkuk University Medical Center Seoul Korea

    26 shared publications
  • Sung Hee Choi

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

    18 shared publications
  • Young Min Cho

    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    18 shared publications
  • Hak Chul Jang

    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    12 shared publications
  • Soo Lim

    Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seongnam Korea

    11 shared publications

Latest Publications

  • Open Access

    Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

    by Soo Heon Kwak, KyungWan Min, Bon Jeong Ku, Ji A Seo, Sang Yong Kim, Sang Youl Rhee, Gyuri Kim, Jae Hyoung Cho, Sang‐Ah Chang, Sung Hee Choi, et al.

    Introduction: This study investigated the efficacy and safety of teneligliptin as an add‐on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. Materials and Methods: In this multicenter, double‐blind, randomized, placebo‐controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0–10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily ( n = 116) or placebo ( n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters. Results: At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least‐squares mean difference −0.69%; 95% confidence interval −0.83 to −0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment‐emergent adverse events between the groups. Discussion: The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.

  • Genomic and multi-omic insights into the heterogeneity of diabetic kidney disease

    by Jae Hyun Bae, Raymond J. Kreienkamp, Mathula Muhundan, Miriam S. Udler, Soo Heon Kwak

    Diabetic kidney disease (DKD) is a leading cause of kidney failure and excess morbidity and mortality. Once regarded as a uniform microvascular complication of chronic hyperglycaemia, DKD is now recognized as a biologically and clinically heterogeneous condition. Not all chronic kidney disease in individuals with diabetes can be attributed to diabetes, and distinguishing DKD from non-diabetic kidney disease (non-DKD) is essential for appropriate management. Multiple interacting pathways, including hyperglycaemia, haemodynamic stress, dyslipidaemia, obesity, inflammation and ancestry-specific genetic risk, drive diverse patterns of kidney injury and clinical trajectories. Conventional classification based on glomerular filtration rate or albuminuria alone fails to capture this complexity. Emerging multi-omics approaches are reshaping our understanding of DKD by identifying genomic, epigenomic, proteomic and metabolomic signatures that stratify risk, elucidate mechanisms and inform therapeutic response. Integration of these molecular layers with polygenic scores, data-driven clustering and single-cell kidney atlases is beginning to define disease endotypes and guide precision-medicine strategies. Large-scale collaborative efforts that combine deep phenotyping, biobanking and advanced analytics are accelerating the translation of molecular heterogeneity into actionable biomarkers and therapeutic targets. Despite ongoing challenges — including the need for validation, equitable representation and clinical implementation — omics-driven precision approaches offer the potential to transform DKD management by reducing residual risk and enabling more effective, precision interventions.

  • Letter to the Members of the American Diabetes Association Board of Directors

    by David D’ALessio, Jonathan Campbell, Lisa Chow, Steven Crowley, Dawn Belt Davis, Jennifer Estall, Carmella Evans-Molina, Rana Gupta, Kirk Habbeger, Rebecca Haeusler, et al.

  • Metformin Use Before Assisted Reproductive Technology and Pregnancy Outcomes in Women With Polycystic Ovary Syndrome: A Nationwide Cohort Study

    by Yongtai Cho, Yeon Soo Park, Yubin Lee, HyunJoo Lim, Ju‐Young Shin, Soo‐Heon Kwak

    Metformin has been hypothesized to improve ovulation and pregnancy rates in women with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology (ART). This population‐based cohort study assessed pregnancy outcomes associated with metformin use prior to ART in women with PCOS. We included 10,178 women with PCOS undergoing their first fresh embryo transfer cycle under the national health insurance program of South Korea between 2017 and 2021. Women who received metformin for ovulation induction within 12 weeks prior to ovarian stimulation were compared with those who did not receive metformin. ART outcomes included successful oocyte retrieval, embryo transfer, and clinical pregnancy, while pregnancy outcomes included spontaneous abortion, preterm birth, and live birth. Overlap‐weighted risk ratios (RR) were calculated for each outcome. Among the study population, 2,149 (21.1%) had used metformin prior to ovarian stimulation, and 8,029 (78.9%) had not. Metformin use did not improve or worsen ART outcomes, with comparable rates of oocyte retrieval (RR: 1.01, 95% confidence interval 1.00–1.02) and clinical pregnancy (RR: 1.05, 1.00–1.11), as well as no increased rates of spontaneous abortion (RR: 1.01, 0.84–1.21), preterm birth (RR: 0.99, 0.84–1.18), or live birth (RR: 1.05, 0.99–1.12). Subgroup analyses suggested modest benefits, including higher clinical pregnancy or live birth rates, among women aged ≥ 35 years, those undergoing a GnRH antagonist protocol, and those with ≥ 30 days of metformin use. In conclusion, metformin pretreatment before ART was not associated with any clinically meaningful benefits or harms in pregnancy outcomes among women with PCOS.

  • Three-Year Glycemic Trajectories in Subgroups With Type 1 Diabetes at Risk for Suboptimal Glycemic Control: A Multicenter Continuous Glucose Monitoring Study

    by Jee Hee Yoo, Seohyun Kim, Yeonsoo Park, Soojin Park, Choon Hee Chung, Jae Hyeon Kim, Soo Heon Kwak, Gyuri Kim

    OBJECTIVE: To examine 3-year longitudinal trajectories of continuous glucose monitoring (CGM) metrics across subgroups at risk for suboptimal glycemic control among adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this multicenter study, 1,028 individuals contributed 3,441 longitudinal CGM profiles. Participants were stratified on the basis of age, chronic kidney disease (CKD), β-cell function, BMI, and triglyceride-glucose (TyG) tertile. Linear mixed-effects models were used to estimate subgroup differences in longitudinal changes. RESULTS: At baseline, there was more time spent with glucose above target range (>180 mg/dL), for the subgroups of older age, CKD, severe β-cell failure, higher BMI, and highest TyG tertile (all P < 0.05), while severe β-cell failure was additionally associated with more time spent with glucose below target range (time below range [TBR]) (<70 mg/dL), along with greater glycemic variability (all P < 0.001). In relation to younger individuals, for older adults, improvement in time spent with glucose in target range (time in range [TIR]) (70–180 mg/dL) was comparable (β = 0.110; P = 0.102) and lower TBR was maintained (3.5% vs. 1.7%, respectively; P < 0.001). Among the CKD group, significant improvement in TIR was seen (β = 0.228; P = 0.002) without exacerbation of hypoglycemia. Severe β-cell failure attenuated TIR improvement (β = −0.119; P = 0.025) and TBR reduction (β = 0.046; P < 0.001). Lower absolute TIR was seen for those with higher BMI and those in the highest TyG tertile. Greater TIR improvement was observed for those in the highest TyG tertile (β = 0.083; P = 0.001). CGM metrics varied widely within these subgroups. CONCLUSIONS: Older age and CKD were associated with longitudinal glycemic improvement without worsening of hypoglycemia, whereas severe β-cell failure limited glycemic gains; substantial within-group heterogeneity supports individualized glycemic targets informed by CGM trajectories in type 1 diabetes.

  • The Burden and Phenotype of Type 2 Diabetes in the Western Pacific Region

    by Andrea On Yan Luk, Lee-Ling Lim, Juliana Chung Ngor Chan, Edith Wing Kar Chow, Soo Heon Kwak, Rinki Murphy

    The International Diabetes Federation estimated that in 2024, 215 million adults—more than one-third of the global diabetes population—were living with diabetes within the Western Pacific Region (WPR), which includes nations with some of the highest prevalence worldwide. Rapid urbanization and economic development have profoundly reshaped lifestyles, which interact with biological predispositions resulting in an earlier onset of type 2 diabetes. These predispositions are not uniform across the heterogeneous populations within the WPR. Asian individuals tend to have a β-cell secretory failure phenotype with type 2 diabetes arising at lower adiposity, distinct from the high-adiposity phenotype with pronounced insulin resistance common among Pacific peoples. Improvements in diabetes care in high-income countries have reduced vascular complications and improved survival, shifting the clinical profile of individuals with type 2 diabetes toward an older population characterized by multimorbidity. In contrast, low-income settings continue to face a high prevalence of type 2 diabetes, compounded by limited access to medications and diagnostic tools, shortage of trained health care professionals, and other logistical barriers to care. In this diverse region where countries are at different stages of health care development, there are considerable opportunities for sharing of best practices through collaborative and translational research. These may include social and public health policies, health care delivery, use of registers to track disease patterns and care standards, and use of technologies to support self-management. For implementation of these actions, a major shift is required, toward prevention, capacity building, and demonstrating the impact of value-based prevention and data-driven care.

  • The Gain-of-Function GLP1R R131Q Variant Preserves β-Cell Function and Enhances Response to GLP-1 Receptor Agonists

    by Hyunsuk Lee, Hannah E. Christie, Ji Seon Lee, Woo-Il Kwon, Min Kyong Moon, Sung Hee Choi, Dae Ho Lee, Seunggeun Lee, Hyunbeom Lee, Minjung Kho, et al.

    OBJECTIVE: Genetic variation in the glucagon-like peptide 1 receptor (GLP1R) has been implicated in type 2 diabetes (T2D) risk and treatment response. We investigated whether GLP1R R131Q, which was previously reported as a T2D-protective variant in genome-wide association studies, alters receptor signaling, β-cell function, and response to glucagon-like peptide 1 receptor agonists (GLP-1RAs). RESEARCH DESIGN AND METHODS: Trajectory of β-cell function was evaluated in a 20-year community-based prospective cohort in Korea (n = 6,373), where participants underwent biennial 2-h 75-g oral glucose tolerance tests, and disposition index was used as surrogate marker. Pharmacogenetic response to GLP-1RAs was assessed in a hospital-based T2D cohort in Korea (n = 177). Hyperglycemic clamp studies (n = 17), human islet experiments (n = 21), and in vitro assays were conducted to characterize GLP1R R131Q effects on receptor signaling and islet function. RESULTS: GLP1R R131Q was associated with slower decline in disposition index in individuals without T2D, with reductions from baseline of 30% in homozygous carriers, 35% in heterozygotes, and 37% in wild-type individuals. In people with T2D, each allele conferred an additional 0.53% or 5.8 mmol/mol reduction in HbA1c after 6 months of GLP-1RA treatment (P = 5.8 × 10−4). Hyperglycemic clamp and human islet experiments demonstrated allele-dependent enhancement of GLP-1RA–stimulated insulin secretion (P = 0.050 and P = 0.037, respectively). In vitro, GLP1R R131Q increased GLP-1RA–stimulated cAMP production with directional observations consistent with pathway bias. CONCLUSIONS: GLP1R R131Q is a gain-of-function variant associated with preservation of β-cell function and enhanced glycemic response to GLP-1RA treatment, supporting further investigation as a candidate pharmacogenetic marker for precision diabetes care.


  • Open Access

    Multi-ancestry, trans-generational GWAS meta-analysis of gestational diabetes and glycaemic traits during pregnancy reveals limited evidence of pregnancy-specific genetic effects

    by Caroline Brito Nunes, Valentina Rukins, Aminata H. Cisse, Frédérique White, Nancy McBride, Alan Kuang, Catherine Allard, Justiina Ronkainen, Alice Hughes, Amanda Elliott, et al.

    Gestational diabetes mellitus (GDM) affects ~14% of pregnancies and increases maternal type 2 diabetes mellitus (T2DM) risk. The GenDiP Consortium presents trans-generational, multi-ancestry genome-wide association study meta-analyses of GDM and pregnancy glycemic traits in up to 38,305 GDM cases and 776,145 controls. We identify 37 GDM-associated loci (7 novel) and five novel loci for pregnancy glycemic traits, all operating through the maternal genome. We classify 12 GDM variants with stronger effects in GDM than T2DM into five biologically informed categories, revealing pleiotropy patterns, pregnancy-dependent effect modification, and diagnostic heterogeneity. While all these loci overlap with T2DM and/or non-pregnant glycaemic traits, four (G6PC2, CAST-PCSK1, HKDC1, FOXA2) lack genome-wide-significant T2DM associations; GCK shows distinct causal variants for GDM, and MTNR1B exhibits pregnancy-amplified effects. Our findings provide new genetic insights into GDM and highlight the need for larger, ancestrally diverse studies of GDM and glycaemic traits during pregnancy to understand potential pregnancy-specific effects.


  • Open Access

    Genetic and Lifestyle Factors Influence High 1-Hour Plasma Glucose, a Predictor of Type 2 Diabetes Mellitus

    by Soobin Cho, Hyunsuk Lee, Joon Ha, Yeonsoo Park, Joon Ho Moon, Hak Chul Jang, Kyong Soo Park, Nam H. Cho, Michael Bergman, Soo Heon Kwak

    Background: High 1-hour plasma glucose (1-h PG) level has been proposed by the International Diabetes Federation to identify high-risk individuals and diagnose type 2 diabetes mellitus (T2DM). In a longitudinal cohort, we examined T2DM risk, β-cell function, and the effects of genetic and lifestyle factors on high 1-h PG.Methods: We analyzed 7,464 participants without T2D at baseline from a community-based prospective cohort in Korea, who underwent biennial 2-h 75-g oral glucose tolerance tests over 14 years. Incident T2D risk were assessed across 1-h PG groups: < 155, 155–208, and ≥ 209 mg/dL. In 6,588 participants with at least two 1-h PG measurements, we analyzed 1-h PG trajectories by T2D polygenic risk score (PRS; low, 1st quintile; intermediate, 2nd–4th quintiles; high, 5th quintile) and lifestyle, assessed using Life's Essential 8.Results: Compared to the <155 mg/dL group, hazard ratios for T2DM were 3.34 (95% confidence interval [CI], 2.99 to 3.74; P<0.001) for 155–208 mg/dL, and 6.81 (95% CI, 5.81 to 7.98; P<0.001) for ≥209 mg/dL. Both groups had lower baseline disposition index compared to the <155 mg/dL group (57.3% and 72.7%, respectively; both P<0.001). Higher T2DM PRS was associated with elevated baseline 1-h PG (low: 131 mg/dL, intermediate: 141 mg/dL, high: 151 mg/dL) and faster increase in 1-h PG (1.36 vs. 1.85 vs. 2.21 mg/dL/year; all P<0.001). Importantly, healthy lifestyle attenuated the rate of increase across all PRS groups.Conclusion: High 1-h PG predicts T2DM risk and is associated with β-cell dysfunction. The 1-h PG level is influenced by genetic risk and can be modified with a healthy lifestyle.

  • Open Access

    Polygenic risk score refines cardiovascular disease risk in individuals with type 2 diabetes at borderline or intermediate risk

    by Jaewon Choi, Hyunsuk Lee, Tae‐Min Rhee, Jun‐Bean Park, Soo Heon Kwak

    To evaluate whether a coronary artery disease (CAD) polygenic risk score (PRS) can improve atherosclerotic cardiovascular disease (ASCVD) risk stratification in individuals with type 2 diabetes (T2D), particularly those at borderline or intermediate 10‐year risk. In the UK Biobank ( n = 340,299), we integrated CAD PRS into the Pooled Cohort Equations (PCE) to evaluate whether it improved the prediction of incident ASCVD in individuals with T2D at borderline and intermediate 10‐year risk. CAD PRS was associated with ASCVD in T2D (1.18‐fold). Among those at borderline and intermediate risk, PRS was strongly predictive (1.47‐fold and 1.11‐fold), and individuals in the top 10% had 1.86‐fold and 1.32‐fold higher risk. Integration of PRS into PCE modestly improved AUROC (0.050, P = 0.024) and significantly improved net reclassification (0.343, P = 2.62 × 10 −4 ). CAD PRS enhances ASCVD risk prediction in individuals with T2D, supporting utilizing genetic information in tailored risk stratification and preventive care.